We are live on
!
Find out more
GCM
Glenview Capital Management Portfolio holdings
AUM
$3.98B
1-Year Est. Return
20.52%
This Fund
S&P 500
This Quarter
Est. Return
+2.47%
1 Year Est. Return
+20.52%
3 Year Est. Return
+68.18%
5 Year Est. Return
+87.14%
10 Year Est. Return
+400.35%
AUM
$18.5B
AUM Growth
+$1.26B
(+7.3%)
Cap. Flow
+$569M
Cap. Flow
% of AUM
3.08%
Top 10 Holdings %
Top 10 Hldgs %
44.15%
Holding
64
New
8
Increased
19
Reduced
25
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Newell Brands
NWL
|
+$587M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
+$478M |
| 3 |
CVS Health
CVS
|
+$396M |
| 4 |
AGN
Allergan plc
AGN
|
+$207M |
| 5 |
Universal Health Services
UHS
|
+$195M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$375M |
| 2 |
Zimmer Biomet
ZBH
|
+$369M |
| 3 |
Lowe's Companies
LOW
|
+$235M |
| 4 |
HCA Healthcare
HCA
|
+$225M |
| 5 |
Apple
AAPL
|
+$205M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.93% |
| 2 | Materials | 12.42% |
| 3 | Technology | 8.98% |
| 4 | Communication Services | 8.9% |
| 5 | Consumer Discretionary | 6.94% |
Similar funds
MAM
USCWA
AI
LWCA
JSW
AS
BWA
BCP
Glenview Capital Management's Q4 2017 Portfolio in Review
As of Q4 2017, Glenview Capital Management held 64 positions worth $18.5B, up 7.3% from $17.2B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Glenview Capital Management deployed $569M of net new capital in Q4 2017, opening 8 new positions and adding to 19 existing holdings. Its largest new stake was Newell Brands: 17,012,932 shares worth $526M.
By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 43% a quarter earlier, followed by Materials and Technology.
On the sell side, the largest reduction was AbbVie, an estimated $375M trimmed.
- Glenview Capital Management's largest Q4 2017 buy was Newell Brands: 17,012,932 shares worth $526M.
- Glenview Capital Management added most to Walgreens Boots Alliance in Q4 2017, an estimated $478M increase.
- Glenview Capital Management's biggest Q4 2017 reduction was AbbVie, cutting an estimated $375M.
- Glenview Capital Management fully exited Zimmer Biomet in Q4 2017, selling an estimated $369M.
- Glenview Capital Management's ten largest holdings make up 44% of its $18.5B portfolio in Q4 2017.
- Glenview Capital Management opened 8 new positions and closed 6 in Q4 2017.
- Glenview Capital Management's portfolio value rose 7.3% quarter-over-quarter to $18.5B.
Based on Glenview Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.